|
Adenoid Cystic Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinically significant copy number alterations and complex rearrangements of MYB and NFIB in head and neck adenoid cystic carcinoma.
|
22505352 |
2012 |
|
Adenoid Cystic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A significant portion of adenoid cystic carcinoma (ACC) cases are characterized by a t(6;9)(q22-23;p23-24) translocation that originates a MYB-NFIB fusion oncogene.
|
26309189 |
2015 |
|
Adenoid Cystic Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CRTC1/MAML2 and MYB/NFIB were also analyzed in MEC and adenoid cystic carcinoma cases, respectively.
|
28139061 |
2017 |
|
Adenoid Cystic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The majority of adenoid cystic carcinomas (AdCCs), regardless of anatomical site, harbour the MYB-NFIB fusion gene.
|
23398044 |
2013 |
|
Adenoid Cystic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Moreover, MYB-NFIB and EWSR1-ATF1 gene fusions were shown to be specifically found in cases of adenoid cystic carcinomas and hyalinizing clear cell carcinomas, respectively, in the context of salivary gland tumors, becoming reliable diagnostic tools for these entities and potential therapeutic targets for future therapeutic protocols.
|
25990369 |
2016 |
|
Adenoid Cystic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We show that the t(6;9)(q22-23;p23-24) translocation in adenoid cystic carcinomas (ACC) of the breast and head and neck consistently results in fusions encoding chimeric transcripts predominantly consisting of MYB exon 14 linked to the last coding exon(s) of NFIB.
|
19841262 |
2009 |
|
Adenoid Cystic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Breast adenoid cystic carcinoma (ACC) is a primary breast carcinoma that, like salivary gland ACC, displays the t(6;9) translocation resulting in the MYB-NFIB gene fusion and immunopositivity for MYB by immunohistochemistry (IHC).
|
28498281 |
2017 |
|
Adenoid Cystic Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations.
|
26631609 |
2016 |
|
Adenoid Cystic Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
RNA-sequencing and whole-genome sequencing revealed no definite alternative driver in the fourth AdCC studied, despite high levels of MYB expression and the activation of pathways similar to those activated in MYB-NFIB-positive AdCCs.
|
29149504 |
2018 |
|
Adenoid Cystic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Adenoid cystic carcinoma (AdCC) is a rare type of triple-negative breast cancer (TNBC) characterized by the presence of the MYB-NFIB fusion gene.
|
26095796 |
2015 |
|
Adenoid Cystic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
NFIB-associated gene rearrangement is a frequent genetic event in vulvar adenoid cystic carcinomas.
|
27662035 |
2017 |
|
Adenoid Cystic Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Two prior studies showed t(6;9)/MYB-NFIB in tracheobronchial adenoid cystic carcinoma; however, only rare cases of MYBL1 rearrangement have been reported in this carcinoma.
|
31028361 |
2019 |
|
Adenoid Cystic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
For instance, secretory carcinomas of the breast consistently harbour the t(12;15) translocation that leads to the formation of the ETV6-NTRK3 fusion gene, adenoid cystic carcinomas consistently display the t(6;9) MYB-NFIB translocation and lobular carcinomas consistently show inactivation of the CDH1 gene through multiple molecular mechanisms.
|
20452298 |
2010 |
|
Adenoid Cystic Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The MYB-NFIB fusion gene was detected in both adenoid cystic carcinomas and their associated high-grade triple-negative breast cancer components.
|
27491809 |
2016 |
|
Adenoid Cystic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Adenoid cystic carcinomas (ACCs) from various anatomical sites harbor a translocation t(6;9)(q22-23;p23-24), resulting in MYB-NFIB gene fusion.
|
25217885 |
2014 |
|
Adenoid Cystic Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
The mutational landscape of adenoid cystic carcinoma.
|
23685749 |
2013 |
|
Adenoid Cystic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MYB-NFIB gene fusions identified in archival adenoid cystic carcinoma tissue employing NanoString analysis: an exploratory study.
|
31301736 |
2019 |
|
Adenoid Cystic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To investigate genetic alterations in lacrimal gland adenoid cystic carcinomas (ACCs) with emphasis on the MYB-NFIB fusion oncogene and its downstream targets, MYB rearrangements, and copy number alterations in relation to clinical data and survival.
|
23725736 |
2013 |
|
Adenoid Cystic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our data further demonstrated that the MYB/NFIB translocation is not necessarily an early event or fundamental for the progression to adenoid cystic carcinoma with high-grade transformation.
|
24732452 |
2014 |
|
Adenoid Cystic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance.
|
20702610 |
2010 |
|
Adenoid Cystic Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
For example, the MYB-NFIB fusion in adenoid cystic carcinoma is regulated by IGF1R through an autocrine loop, and IGF1R is a downstream target of the EWSR1-WT1 and PAX3-FKHR fusions in desmoplastic small round cell tumors and alveolar rhabdomyosarcoma, respectively.
|
31426421 |
2019 |
|
Adenoid Cystic Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MYB-NFIB fusion was detected in 57/85 (67.1%), MYBL1-NFIB fusion in 12/85 (14.1%), MYB-X fusion in 4/85 (4.7%), MYBL1-X in 4/85 (4.7%), and NFIB-X in 2/85 (2.4%) of AdCC cases.
|
29619555 |
2018 |
|
Adenoid Cystic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A t(6;9)(q22-23;p23-34) translocation resulting in a MYB-NFIB gene fusion has been identified in the majority of adenoid cystic carcinomas.
|
29076877 |
2018 |
|
Adenoid Cystic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The defining molecular feature of adenoid cystic carcinoma is the presence of a recurrent chromosomal translocation, t(6; 9) (q22-23; p23-24), with the fusion transcript involving the genes MYB and NFIB.
|
23222122 |
2013 |
|
Adenoid Cystic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MYB-NFIB gene rearrangement occurs in 30-86% of salivary gland adenoid cystic carcinomas.
|
31189999 |
2019 |